IL238095B - Proteolytic inactivation of selected proteins in bacterial extraction to improve expression - Google Patents

Proteolytic inactivation of selected proteins in bacterial extraction to improve expression

Info

Publication number
IL238095B
IL238095B IL23809515A IL23809515A IL238095B IL 238095 B IL238095 B IL 238095B IL 23809515 A IL23809515 A IL 23809515A IL 23809515 A IL23809515 A IL 23809515A IL 238095 B IL238095 B IL 238095B
Authority
IL
Israel
Prior art keywords
improved expression
bacterial extracts
proteolytic inactivation
select proteins
proteins
Prior art date
Application number
IL23809515A
Other languages
English (en)
Hebrew (he)
Other versions
IL238095A0 (en
Inventor
D Thanos Christopher
J Murray Christopher
Yang Junhao
stephenson Heather
Original Assignee
Sutro Biopharma Inc
D Thanos Christopher
J Murray Christopher
Yang Junhao
stephenson Heather
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sutro Biopharma Inc, D Thanos Christopher, J Murray Christopher, Yang Junhao, stephenson Heather filed Critical Sutro Biopharma Inc
Publication of IL238095A0 publication Critical patent/IL238095A0/en
Publication of IL238095B publication Critical patent/IL238095B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245Escherichia (G)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00Preparation of peptides or proteins
    • C12P21/02Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02Column chromatography
    • G01N30/04Preparation or injection of sample to be analysed
    • G01N30/06Preparation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/50Fusion polypeptide containing protease site
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
IL23809515A 2012-10-12 2015-04-01 Proteolytic inactivation of selected proteins in bacterial extraction to improve expression IL238095B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261713245P 2012-10-12 2012-10-12
PCT/US2013/063804 WO2014058830A1 (en) 2012-10-12 2013-10-08 Proteolytic inactivation of select proteins in bacterial extracts for improved expression

Publications (2)

Publication Number Publication Date
IL238095A0 IL238095A0 (en) 2015-05-31
IL238095B true IL238095B (en) 2019-11-28

Family

ID=49447839

Family Applications (1)

Application Number Title Priority Date Filing Date
IL23809515A IL238095B (en) 2012-10-12 2015-04-01 Proteolytic inactivation of selected proteins in bacterial extraction to improve expression

Country Status (14)

Country Link
US (3) US9650621B2 (https=)
EP (1) EP2906592B1 (https=)
JP (3) JP6421122B2 (https=)
KR (1) KR102018863B1 (https=)
CN (1) CN104837863B (https=)
AU (1) AU2013329464C1 (https=)
CA (1) CA2887355C (https=)
DK (1) DK2906592T3 (https=)
ES (1) ES2694683T3 (https=)
HU (1) HUE041721T2 (https=)
IL (1) IL238095B (https=)
PL (1) PL2906592T3 (https=)
SG (1) SG11201502875VA (https=)
WO (1) WO2014058830A1 (https=)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6421122B2 (ja) 2012-10-12 2018-11-07 ストロ バイオファーマ, インコーポレイテッド 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化
CA2909516C (en) * 2013-04-19 2023-03-07 Sutro Biopharma, Inc. Expression of biologically active proteins in a bacterial cell-free synthesis system using cell extracts with elevated levels of exogenous chaperones
US10316322B2 (en) * 2014-07-02 2019-06-11 Sutro Biopharma, Inc. High growth capacity auxotrophic Escherichia coli and methods of use
EP3882343A3 (en) * 2016-01-13 2021-12-08 New England Biolabs, Inc. Thermostable variants of t7 rna polymerase
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN106801047A (zh) * 2016-12-30 2017-06-06 武汉金开瑞生物工程有限公司 一种通过无细胞蛋白合成系统制备半胱氨酸蛋白酶的方法
ES3024474T3 (en) 2016-12-30 2025-06-04 Vaxcyte Inc Polypeptide-antigen conjugates with non-natural amino acids
AU2018300069C1 (en) 2017-07-11 2025-11-20 Synthorx, Inc. Incorporation of unnatural nucleotides and methods thereof
WO2019028419A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
SG11202003147XA (en) 2017-10-12 2020-05-28 Vaxcyte Inc Periodontitis vaccine and related compositions and method of use
CA3091857A1 (en) 2018-02-26 2019-08-29 Synthorx, Inc. Il-15 conjugates and uses thereof
WO2020014543A2 (en) 2018-07-11 2020-01-16 Actym Therapeutics, Inc. Engineered immunostimulatory bacterial strains and uses thereof
CN108949796A (zh) * 2018-07-27 2018-12-07 张家港市华天药业有限公司 一种用于合成谷胱甘肽的重组菌及谷胱甘肽的合成方法
CN109055291A (zh) * 2018-07-31 2018-12-21 张家港市华天药业有限公司 用于合成谷胱甘肽的重组菌及谷胱甘肽的合成方法
ES3059360T3 (en) 2018-11-08 2026-03-19 Synthorx Inc Interleukin 10 conjugates and uses thereof
KR20260039812A (ko) 2019-02-06 2026-03-20 신톡스, 인크. Il-2 콘쥬게이트 및 이의 사용 방법
WO2020205584A1 (en) 2019-04-02 2020-10-08 Vaxcyte, Inc. Optimized cell-free synthesis of invasion plasmid antigen b and related compositions and methods of use
CN114555128A (zh) 2019-08-15 2022-05-27 新索思股份有限公司 采用il-2缀合物的免疫肿瘤学组合疗法
MX2022002740A (es) 2019-09-10 2022-03-25 Synthorx Inc Conjugados de il-2 y metodos de uso para tratar enfermedades autoinmunes.
IL291786A (en) 2019-11-04 2022-06-01 Synthorx Inc Interleukin 10 conjugates and their use
US12351850B2 (en) * 2020-04-30 2025-07-08 Sutro Biopharma, Inc. Methods of producing full-length antibodies using E. coli
JP2023531509A (ja) 2020-06-25 2023-07-24 シンソークス, インコーポレイテッド Il-2コンジュゲートおよび抗egfr抗体を用いる免疫腫瘍学併用療法
CA3192331A1 (en) 2020-09-14 2022-03-17 Sutro Biopharma, Inc. Method for large scale production of antibodies using a cell-free protein synthesis system
WO2022076859A1 (en) 2020-10-09 2022-04-14 Synthorx, Inc. Immuno oncology therapies with il-2 conjugates
AU2021356693A1 (en) 2020-10-09 2023-06-15 Synthorx, Inc. Immuno oncology combination therapy with il-2 conjugates and pembrolizumab
EP4291243A1 (en) 2021-02-12 2023-12-20 Synthorx, Inc. Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
TW202245843A (zh) 2021-02-12 2022-12-01 美商欣爍克斯公司 Il-2接合物及西米普利單抗(cemiplimab)之皮膚癌組合療法
CN113322267B (zh) * 2021-03-15 2024-01-05 天津大学 系统在提高非天然氨基酸的插入效率中的应用
EP4346904A1 (en) 2021-06-03 2024-04-10 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
US20250302950A1 (en) 2021-12-20 2025-10-02 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
WO2024136899A1 (en) 2022-12-21 2024-06-27 Synthorx, Inc. Cancer therapy with il-2 conjugates and chimeric antigen receptor therapies
TW202444349A (zh) 2023-03-20 2024-11-16 美商欣爍克斯公司 使用il-2綴合物之癌症療法
WO2025015041A1 (en) * 2023-07-12 2025-01-16 University Of Washington Rna-only, positive control target for clinical diagnostic testing
WO2025158385A1 (en) 2024-01-25 2025-07-31 Genzyme Corporation Pegylated il-2 for suppressing adaptive immune response to gene therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100445394C (zh) * 1999-03-04 2008-12-24 阿斯比奥制药株式会社 控制OmpT蛋白酶切割的方法
DE60226411D1 (de) 2001-01-25 2008-06-19 Anthony C Forster Verfahren und zusammensetzungen für peptid-, protein- und peptidomimetische synthese
ATE445699T1 (de) 2002-08-19 2009-10-15 Univ Leland Stanford Junior Verbesserte verfahren zur in-vitro- proteinsynthese
DE10336705A1 (de) * 2003-08-06 2005-03-10 Rina Netzwerk Rna Technologien Verfahren zur Herstellung eines Lysats zur zellfreien Proteinbiosynthese
AU2004276687B2 (en) * 2003-09-30 2011-07-14 Asubio Pharma Co., Ltd. Method of cleaving polypeptide by using OmpT protease mutant
WO2006082059A1 (en) * 2005-02-02 2006-08-10 Universität Bayreuth Esterases for monitoring protein biosynthesis in vitro
US8367588B2 (en) 2005-10-12 2013-02-05 The Scripps Research Institute Selective posttranslational modification of phage-displayed polypeptides
KR20080113226A (ko) 2006-03-16 2008-12-29 더 스크립스 리서치 인스티튜트 비천연 아미노산 페닐셀레노시스테인을 함유하는 단백질의 유전자적으로 프로그램된 발현
CN102348807B (zh) 2009-01-12 2015-04-15 苏特罗生物制药公司 利用体外蛋白合成体系将非天然氨基酸引入蛋白的单装载体系
JP6421122B2 (ja) 2012-10-12 2018-11-07 ストロ バイオファーマ, インコーポレイテッド 改善された発現のための、細菌抽出物中の選択タンパク質のタンパク質分解不活性化

Also Published As

Publication number Publication date
JP6421122B2 (ja) 2018-11-07
JP2018029621A (ja) 2018-03-01
US9650621B2 (en) 2017-05-16
PL2906592T3 (pl) 2019-07-31
DK2906592T3 (en) 2018-12-10
AU2013329464C1 (en) 2018-02-15
CN104837863B (zh) 2018-06-19
CA2887355A1 (en) 2014-04-17
CA2887355C (en) 2023-03-07
KR102018863B1 (ko) 2019-09-05
EP2906592B1 (en) 2018-10-03
US11261219B2 (en) 2022-03-01
HUE041721T2 (hu) 2019-05-28
KR20150064209A (ko) 2015-06-10
US10450353B2 (en) 2019-10-22
US20200062807A1 (en) 2020-02-27
AU2013329464A1 (en) 2015-05-14
EP2906592A1 (en) 2015-08-19
CN104837863A (zh) 2015-08-12
WO2014058830A1 (en) 2014-04-17
IL238095A0 (en) 2015-05-31
AU2013329464B2 (en) 2017-07-27
JP2015531407A (ja) 2015-11-02
JP2021003134A (ja) 2021-01-14
ES2694683T3 (es) 2018-12-26
US20150259664A1 (en) 2015-09-17
US20170283469A1 (en) 2017-10-05
SG11201502875VA (en) 2015-06-29

Similar Documents

Publication Publication Date Title
IL238095A0 (en) Proteolytic inactivation of selected proteins in bacterial extraction to improve expression
IL286784A (en) Compositions of protein and antibody
IL234621A0 (en) Loaded dietary proteins and methods
ZA201408662B (en) Microbial fermentation methods and compositions
PL3346008T3 (pl) Rekombinowane mikroorganizmy oraz ich zastosowania
SG11201501254RA (en) Recombinant microorganisms and uses therefor
ZA201400562B (en) Axmi205 variant proteins and methods for their use
IL230918A0 (en) Modified proteins and peptides
ZA201405858B (en) Recombinant microorganisms and methods of use thereof
EP2670847A1 (en) Methods and materials for enhancing functional protein expression in bacteria
PL2678432T3 (pl) Rekombinowane mikroorganizmy i ich zastosowania
ZA201508529B (en) Bacterial fermentation methods and compositions
PT2665818T (pt) Expressão de proteínas em plantas
PT2804875T (pt) Ferramentas e métodos para expressão de proteínas de membrana
EP2718432A4 (en) NUCLEASE FUSION PROTEIN AND USES THEREOF
IL232759A (en) A method for increased expression of bacterial engineering of recombinant protein and its use
IL231715A (en) Liquid protein supplement that has been sterilized
PL2851083T3 (pl) Kompozycja białkowa odporna na sterylizację promieniowaniem
GB201213672D0 (en) Protein
GB201103169D0 (en) Protein expression
GB201121226D0 (en) Modified proteins and peptides
GB201121233D0 (en) Modified proteins and peptides
GB201215901D0 (en) Protein modification
FI20115950L (fi) Probioottisia bakteereita sisältävä elintarvike

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed